Clinical Trial

A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma

Not Yet Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This is a phase 1/2 multicenter, open-label, first-in-human study of IBI3003. It includes a phase 1 dose escalation and expansion section to identify maximum tolerated dose(MTD)/recommended Phase 2 Dose(RP2D) of IBI3003, plans to enroll 54\~360 subjects, and a phase 2 stage to explore efficacy, safety and tolerability of IBI3003 at RP2D in multiple myeloma
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2026-01-12; most recent amendment 2026-02-24.
Trial Details
NCT Number NCT07336472
Lead Sponsor Fortvita Biologics (USA)Inc.
Conditions Multiple Myeloma
Enrollment 360 participants
Start Date 2026-04-01
Primary Completion 2027-12-31 (estimated)
Study Completion 2028-09-30 (estimated)
Updated on ClinicalTrials.gov 2026-02-25